+34 620 10 75 37info@nanbiosis.com

News U10

News U10

Diabetes mellitus type 1: new system for treatment

The research carried out by the NanoBiocells group, coordinator of NANBIOSIS U10 Drug Formulation unit, from CIBER-BBN and UPV-EHU, with BIOMICS group of UPV-EHU was yesterday highlighted in Catalunya Vanguardista and Noticiasdelaciencia.com.

The research reduces the volume of implantation of microcapsules containing insulin-producing pancreatic cells by almost 80% thanks to an innovative system of Magnetic separation of microcapsules. In this way, the medical complications derived from the implantation of large volumes of microcapsules decrease and the treatment of type 1 diabetes mellitus improves.

More information:
https://www.catalunyavanguardista.com/nuevo-sistema-para-el-tratamiento-de-diabetes-mellitus-tipo-1/

Read More

Biomedical devices with natural fluorescence for monitoring in the body

Researchers from the NanoBioCel and the ICTS NANBIOSIS through the Drug Formulation Unit 10 of CIBER-BBN and the University of the Basque Country (UPV/EHU), together with the University of Michigan (USA), have developed a biomedical cellular immunoisolation device (microcapsules) with intrinsic capacity to be traced once implanted in the organism. The novel design incorporates a natural substance called genipine, which emits intense and stable fluorescence in the far red range. Drug Formulation Unit 10 of Nanbiosis has worked in the design and development of fluorescent particles for use in experimental animals.

Non-invasive monitoring of implanted hydrogel-based biosystems generally requires indirect vehicle or load marking, which increases complexity and the potential risk of altering their functionality. For the first time, this group of researchers has demonstrated that hydrogel-based biosystems can be produced from biomaterials with intrinsic properties for non-invasive monitoring, in this case through the use of genipine.

The work has recently been published in the Journal of Biophotonics and has been selected by the journal as a cover story in April.

It is important to note that to date no one has exploited the natural fluorescence emitted by genipine as a non-invasive monitoring system in cell therapies implanted in living beings,” the researchers point out. As a first milestone in this sense, we have developed a novel immunoisolation device that incorporates genipine into its own design, making it traceable once implanted in the body. Using a fast, efficient and non-cytotoxic procedure, we have managed to maximize the fluorescence of the microcapsules until an excellent signal-to-noise ratio is achieved. In addition, the group have validated the use of genipine as a quantitative imaging probe, demonstrating that intense and stable fluorescence is obtained with good signal linearity against doses of microcapsules implanted for several weeks. Through this strategy, they have been able to evaluate the actual injected dose immediately and control its position over time, which significantly improves the biosafety and efficacy of the therapy.

In addition, the idea may have a potentially successful application in the nano, micro and macro hydrogel-based technologies industry. These are called to be fundamental pieces both for biomedical research and for the advancement of clinical medicine through applications such as tissue engineering, regenerative medicine. “As fluorescence imaging systems are gradually implemented in clinical practice, we believe that our proposal could have a successful applicability in advancing multiple hydrogel-based biotechnologies, including drug and cell delivery systems, vaccines or biosensors,” they conclude.

Article of reference :

Edorta Santos‐Vizcaino, Henry Haley, Ainhoa Gonzalez‐Pujana, Gorka Orive, Rosa Maria Hernandez, Gary D. Luker, Jose Luis Pedraz. Monitoring implantable immunoisolation devices with intrinsic fluorescence of genipin. Journal of Biophotonics (April 2019) DOI: https://doi.org/10.1002/jbio.201800170

Read More

Micro and nanotechnologies for the release of biotechnological products

José Luis Pedraz, Scientific Director of NANBIOSIS Unit 10, Drug formulation, talks in this video about Micro and polymeric nanoparticles, lipid nanoparticles, non-viral vectors for gene therapy and scaffolds for cell therapy and regenerative medicine and bio 3D printing

 

Read More

NANOMEDICINE APPLICATIONS IN DRUG DELIVERY AND TARGETING: NANBIOSIS – NANOMED Industrial Forum

Yesterday took place in Barcelona, at Barcelona School of Management, Universitat Pompeu Fabra, a meeting of resarch groups and units of NANBIOSIS and CIBER-BBN and companies in the third B2B Forum organized by NANBIOSIS, in this case together with NANOMED SPAIN.

Thirteen companies and twelve groups from CIBER-BBN and CCMIJU (ten of them coordinating NANBIOSIS units) got together to explain, through short presentations of ten minutes, those lines of their work aimed at finding synergies and potential collaborations in the area of Nanomedicine apllications in drug delivery and targeting. There was also a talk by a  representative of CDTI (Spanish National Center for Industrial and Technological Development) to explain the financing opportunities for the companies as well as a presentation by the NANBIOSIS Coordinator, Jesús Izco, to show the new Cutting Edge Biomedical Solutions offered by the ICTS-NANBIOSIS

After lunch, the groups and companies had the opportunity to discuss in more detail, during bilateral interviews coordinated by NANBIOSIS a, those aspects that had attracted their attention, as well as, in some cases, to draw potential collaborations. The event was successfully developed with 45 attendees and more than 50 individual B2B mettings.

 

Read More

NANBIOSIS working on the development of next generation catheters

NANBIOSIS’ partners CIBER-BBN and JUMISC, with another 44 European partners, led by Philips Electronics Nederland B.V, will work on the development of next genration catheters. 
The project, Position-II  (Ref. n. 783132), that pretends to diversify the production of smart catheters (overcoming the obsolescence of current ones), improve their performance (facilitating their use to be smaller), reduce current production costs and break existing monopolies, has been submitted to the Call for Electronic Components and Systems for European Leadership (ECSEL)- Horizon 2020, with a duration of three years -starting on 1/6/18- and with a budget of over €41M, (€10.4M-financed by European Union)
The objective of the participation of JUMISC in Position-II is to develop new catheters that, in combination with hydrogels and cell therapy, will have a regenerative effect to stimulate the recovery of cardiac areas damaged by heart attacks. NANBIOSIS U10. Drug Formulation, of CIBER-BBN, at UPV-EHU, coordinated by José Luis Pedraz and Jsús Ciriza, will microencapsulate the cells to be test and administered in porcine model  at the JUMISC to validate the designed catheter.
The kick-off of the Eurpean project under Grant Agreement Ecsel-783132- POSOTION II 2017-IA  took place on June 5 to 7 in Rotterdam, representatives of the NANBIOSIS-ICTS  Steering Committee, unit 10 and unit 24 were present.
Read More

DRIVE Project: Artificial Biopancreas for Type I Diabetics

On Saturday, June 2, in the auditorium of the Artium museum in Vitoria, a meeting was held for patients with diabetes, organized by the group of European researchers of the DRIVE project with the aim of conecting patiens with researchers.

The event was organized by the NanoBioCel research group of the CIBER-BBN and the University of the Basque Country, led by José Luis Pedraz, Scientific Director of   NANBIOSIS Unit 10, Drug Formulation, which participates, through the CIBER BBN and the ICTS Nanbiosis, in the Drive Project  focused on pancreatic  cell transplantation  and the development of biomaterials and new surgical devices that improve the transplantation and survival of insulin-producing pancreatic islets for the treatment of diabetes.

Dr. Pedraz explained for EIBT.eus Radio euskadi the aim of the DRIVE project: the transplantation of the cells of the pancreas, which consists of isolating the insulin-producing cells from a donor’s pancreas and implanting them in the patient with daibetes type I, not directly, but introduced into an artificial bio-pancreas by minimal invasive surgery . “Nowadays– explains Dr. Pedraz- obtaining pancreatic cells from stem cells or IPS cells is a not yet controlled process but it is an alternative source of insulin-producing cells. In the DRIVE project the most priority objective is to take the donor cells and introduce them into a device that will allow the patient to produce and release insulin in a more physiological way. In a second phase, it is intended to use differentiated insulin producing cells from the patient’s own cells, thus alleviating the shortage of  donors”.

Read More

New frontiers in the treatment of Diabetes type 1

On Saturday, June 2, at 10.30 in the auditorium of the Artium Museum in Vitoria-Gasteiz, a meeting will take place for patients with diabetes, organized by the group of European researchers of the DRIVE project. The objective of the meeting, held for the first time in Spain, is to connect researchers with all those with diabetes and relatives who want to participate. “One of the objectives of this meeting is to better understand the expectations of people with diabetes and their doubts about the treatment of that disease. By giving us their opinion, they will help us to adapt the DRIVE project to their needs“, explained the organization.
The event is organized by the NanoBioCel research group of the University of the Basque Country / Euskal Herriko Unibertsitatea, directed by José Luis Pedraz, Scientific Director of NANBIOSIS Unit 10, Drug Formulation, who participates in the DRIVE project through the CIBER BBN and the ICTS Nanbiosis, the only Spanish group in the project .
Admission is free and can be obtained at: https://www.ticketea.com/entradas-conferencia-drive-patient-panel/

 

Read More

Nanotechnology, gene therapy, omics therapies and ‘big data’

Nanotechnology, gene therapy, omics therapies and ‘big data’ were the topics discussed in the Forum on Emerging Technologies oganized on May 8 by nanotechnology, gene therapy, omics therapies and ‘big data’ were the topics discussed in the I Forum on Emerging Technologies held on May 8, organized by the CIBER Internationalization Platform, of which the CIBERER, the CIBER-BBN and the CIBERES.

The objective of this event, structured in sessions of presentations and scientific debates about the types of technologies addressed, was to promote the exchange of ideas and scientific knowledge with the aim of generating new collaborations among the CIBER research groups  such as participation in transversal projects or the development of cutting-edge technologies.

NANBIOSIS was represented by Pablo Laguna (Unit 27, High Performance Computing), Laura Lechuga (Unit 4, Biodeposition and Biodetection Unit), José Luis Pedraz (Unit 10, Drug Formulation) and Rosa Villa (Unit8, Micro – Nano Technology Unit)

Read More

Gene therapy in pseudohypoparathyroidism

In 1942, Albright and colleagues described the first hormone resistance syndrome, which they called pseudohypoparathyroidism (PHP) (1), patients had a specific phenotype consisting of short stature, central obesity, round face, short neck and brachydactyly, which is what that today we know like Albright Hereditary Osteodystrophy (AHO, Albright Hereditary Osteodystrophy).

Nanobiocel research group, coordinator of NANBIOSIS U10. Drug Formulation, is working on the project “Gene therapy in pseudohypoparathyroidism: experimental development based on CRISPR / CAS9 and non-viral vectors“.
 The objective of the project is to design and validate the ex vivo gene therapy protocol for the correction of known mutations in the GNAS gene, causing pseudohypoparathyroidism (PHP) type 1A and pseudoPHP, through the following operational objectives: (1) Validation of the model lymphoblasts (immortalized or not) for the application of gene therapy; (2) CRISPR / Cas trial design and vehicularization in non-viral vectors; (3) Identification and characterization of off-target insertions (if any) and (4) Confirmation through functional studies of the correct functioning of the protein obtained from the modified gene.
The project will be carried out by the following research groups: BioAraba of Molecular Epigenetics in rare diseases, led by Dr. Guiomar Pérez de Nanclares, in the OSI Araba – Txagorritxu, the group Nanobiocel, led by Jose Luis Pedraz at UPV/EHU, this group is part of CIBER-BBN and ICTS NANBIOSIS and the group of Professor Cesar Martin, Biofisika Institute (UPV/EHU, CSIC).
Read More

I Forum on Emerging Technologies organized by CIBER

On May 8th, will take place in Madrid, at the Assembly Hall Ernest Lluch of the Instituto de Salud Carlos III, organized by CIBER Internationalization Platform (CIBER-BBN, CIBERER, CIBERES) the I Forum on Emerging Technologies.

The objective of this meeting is to promote the exchange of ideas and scientific knowledge among the CIBER research groups with the aim of generating new collaborations for participation in cross-cutting projects and the development of border technologies. The content of the forum, centered on the type of technology and possibilities it offers, is structured in a program of lectures and scientific debates whose final objective is the discussion and the joint generation of ideas. This first edition of the forum will be focused on Gene Therapy, Nanotechnologies and Omic Technologies-Big Data.

Some Units of NANBIOSIS will participate:

  • José Luis Pedraz, Scientific Director of  Unit 10 Drug Formulation, will speak of “Development of non-viral vectors for gene therapy
  • Laura Lechuga, Scientific Director of Unit 4  Biodepositon and Biodetection, will talk about “Nanodispositive biosensors for advanced clinical diagnosis
  • Rosa Villa, Scientific Director of Unit 8 Micro–Nano Technology, Ramón Martínez, Scientific Director of Unit 26 NMR Biomedical Applications II and Esther Pueyo, researcher of U27 High Performance Computer will moderate the sessions.

 

Programme and registration details

 

Read More